Ovarian Cancer

Brian T. Burgess, DO, first-year fellow, University of Kentucky Markey Cancer Center, discusses resistance to PARP inhibitors in patients with ovarian cancer.

Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the combination of PARP inhibitors and immunotherapy.

Jubilee Brown, MD, Brown explains the value of genetic testing for patients predisposed to and diagnosed with ovarian cancer.

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses studies that demonstrate the value of PARP inhibitors in the treatment of patients with ovarian cancer.

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses improving outcomes with chemotherapy for the neoadjuvant treatment of patients with ovarian cancer.

Matthew Powell, MD, discusses the promise of immunotherapy in ovarian cancer despite its challenges.

Robert L. Coleman, MD, FACOG, FACS, discusses the evolution of treatment for patients with ovarian cancer, the therapies with the most potential, and the importance of classification schemes in directing treatment in recurrent disease.

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the growing potential for personalized treatment in ovarian cancer.

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses data with immunotherapy in ovarian cancer.

Panagiotis A. Konstantinopoulos, MD, PhD, discusses the findings of the TOPACIO/KEYNOTE-162 study and the future for PARP inhibitor combinations and immunotherapy overall in ovarian cancer.

R. Wendel Naumann, MD, discusses the use of neoadjuvant chemotherapy and surgery for patients with ovarian cancer.

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the impact of recent clinical trials in ovarian cancer.

Robert Coleman, MD, professor in the department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the classification of patients with ovarian cancer.

Jubilee Brown, MD, professor of gynecologic oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of genetic testing in patients with ovarian cancer.

Thomas Herzog, MD, traces the therapeutic evolution of frontline treatment for patients with ovarian cancer.

Angeles Alvarez Secord, MD, discusses recent updates in ovarian cancer, with an emphasis on the clinical significance of genetic testing.

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses novel therapies in ovarian cancer.

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the use of neoadjuvant chemotherapy in patients with ovarian cancer.

Robert Coleman, MD, professor in the department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in ovarian cancer.

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses immunotherapy in ovarian cancer.

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the use of biomarkers to guide treatment decisions in patients with ovarian cancer.

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the optimal use of bevacizumab (Avastin) in patients with ovarian cancer.

Ursula A. Matulonis, MD, highlights the activity and tolerability of niraparib and discusses other recent data in ovarian cancer.

Melissa Hardesty, MD, gynecologic oncologist, Alaska Women’s Cancer Center, discusses the safety and efficacy of the bevacizumab/PARP inhibitor combination in ovarian cancer.

Maurie Markman, MD, says that the acceleration in regulatory agency approvals for novel antineoplastic agents and the focus of biomarker discovery proves that this is the era of precision medicine.